Latest Breaking News On - Gautam jayram - Page 1 : comparemela.com

Protara Therapeutics (TARA) Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC

Protara Therapeutics (TARA) Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTimothy lyonJesse sheffermanGautam jayramTherapeutics centerClinical programProtara therapeutics incUrology residency programUrology associatesProtara therapeuticsNon muscle invasive bladder cancerBacillus calmette guAssociate professorUrology residency program directorMayo clinicChief executive officer

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC

Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesGautam jayramJustine omalleyJesse sheffermanKlinische einheitTimothy lyonDrug administrationTherapeutics centerClinical programUrology associatesProtara therapeutics incCompany contactUrology residency programExchange commissionChugai pharmaceutical co ltdNon muscle invasive bladder cancer

Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care

Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.

United statesGautam jayramTherapeutics center at urology associates of nashvilleAdvanced therapeutics centerUrology associatesBacillus calmette guLugpa annual meetingUrothelial cancer

Dr Jayram on the Role of Immunotherapy in Bladder Cancer

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

Gautam jayramUrology associates of nashvilleTherapeutics centerAdvanced therapeutics centerUrology associatesBacillus calmette guerinBladder cancer

Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study

Press release content from Accesswire. The AP news staff was not involved in its creation. Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study January 20, 2021 GMT TORONTO, ON / ACCESSWIRE / January 20, 2021 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (“UA”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG”)-Unresponsive Carcinoma In-Situ (“CIS”) or are intolerant to BCG Therapy (“Study II”).

United statesGautam jayramKristina hacheyCalmette guerinUrology associatesTherapeutic centerTheralase or companyTechnologies incWomen institute for sexual healthUrology surgery centerTherapeutics centerVenture exchangeRegulation services providerTheralase technologies incPhoto dynamic compoundsInstitutional review board